1. Home
  2. CTMX vs YDKG Comparison

CTMX vs YDKG Comparison

Compare CTMX & YDKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • YDKG
  • Stock Information
  • Founded
  • CTMX 2008
  • YDKG 2005
  • Country
  • CTMX United States
  • YDKG China
  • Employees
  • CTMX N/A
  • YDKG N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • YDKG Advertising
  • Sector
  • CTMX Health Care
  • YDKG Consumer Discretionary
  • Exchange
  • CTMX Nasdaq
  • YDKG Nasdaq
  • Market Cap
  • CTMX 596.2M
  • YDKG 715.1M
  • IPO Year
  • CTMX 2015
  • YDKG N/A
  • Fundamental
  • Price
  • CTMX $3.64
  • YDKG $1.40
  • Analyst Decision
  • CTMX Strong Buy
  • YDKG
  • Analyst Count
  • CTMX 6
  • YDKG 0
  • Target Price
  • CTMX $6.50
  • YDKG N/A
  • AVG Volume (30 Days)
  • CTMX 3.9M
  • YDKG 2.1M
  • Earning Date
  • CTMX 11-06-2025
  • YDKG 11-17-2025
  • Dividend Yield
  • CTMX N/A
  • YDKG N/A
  • EPS Growth
  • CTMX 50.22
  • YDKG N/A
  • EPS
  • CTMX 0.24
  • YDKG N/A
  • Revenue
  • CTMX $113,631,000.00
  • YDKG $13,107,000.00
  • Revenue This Year
  • CTMX N/A
  • YDKG N/A
  • Revenue Next Year
  • CTMX N/A
  • YDKG N/A
  • P/E Ratio
  • CTMX $15.28
  • YDKG N/A
  • Revenue Growth
  • CTMX N/A
  • YDKG 2175.52
  • 52 Week Low
  • CTMX $0.40
  • YDKG $1.28
  • 52 Week High
  • CTMX $4.62
  • YDKG $669.00
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 50.34
  • YDKG N/A
  • Support Level
  • CTMX $3.35
  • YDKG N/A
  • Resistance Level
  • CTMX $4.45
  • YDKG N/A
  • Average True Range (ATR)
  • CTMX 0.37
  • YDKG 0.00
  • MACD
  • CTMX -0.06
  • YDKG 0.00
  • Stochastic Oscillator
  • CTMX 30.00
  • YDKG 0.00

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

Share on Social Networks: